Last updated: March 30, 2026
What is Butazolidin?
Butazolidin, chemically known as phenylbutazone, is a non-steroidal anti-inflammatory drug (NSAID). It is used to treat arthritis, gout, and other inflammatory conditions. Developed in the 1950s, it was one of the earliest NSAIDs available commercially.
Regulatory Status and Market Withdrawal
Butazolidin was widely used in the mid-20th century but was withdrawn or heavily restricted in many markets due to safety concerns.
- The U.S. Food and Drug Administration (FDA) withdrew its approval in 2000 because of risks associated with severe adverse effects, including aplastic anemia, agranulocytosis, and other blood dyscrasias.
- In the European Union, use was phased out following safety reviews in the 1990s, with restrictions placed on veterinary applications.
- Despite its withdrawal from human markets in several regions, butazolidin remains authorized for specific veterinary uses in some nations, notably for equine and canine treatments.
Current Market Status
Human Market
- The drug no longer has regulatory approval for human use in major markets (U.S., EU, Canada).
- Limited compounding or off-label use occurs in specific jurisdictions under strict medical oversight.
Veterinary Market
- Approved in select countries for veterinary treatments.
- Revenues are marginal, primarily generated through specialized veterinary pharmaceuticals suppliers.
Market Size and Decline
| Timeline |
Market Status |
Estimated Revenue (USD) |
Notes |
| 1980s |
Commercial human use |
Hundreds of millions |
Leading NSAID, high sales |
| 2000s |
Regulatory withdrawal |
Near zero |
Regulatory bans in major markets |
| 2010s–present |
Specialized veterinary use |
Less than $10 million |
Limited, niche applications |
Factors Influencing Decline
- Safety concerns outweigh benefits.
- Alternative NSAIDs (ibuprofen, naproxen, diclofenac) with better safety profiles are available.
- Regulatory actions restrict or prohibit use in humans.
- Litigation risks increased due to adverse event reports.
Market Drivers and Barriers
Drivers
- Established efficacy: Effective for pain and inflammation.
- Veterinary niche: Used for specific animals under veterinary supervision.
- Research potential: Possibility of reformulation or novel delivery mechanisms.
Barriers
- Safety profile: Severe adverse events significantly limit use.
- Regulatory restrictions: Bans restrict access.
- Market competition: Availability of safer alternatives reduces demand.
- Legal liability: Litigation risk discourages ongoing manufacturing and distribution.
Financial Outlook
Human Market Prognosis
- No significant recovery expected due to regulatory bans and safety issues.
- R&D efforts could explore derivatives or safer analogs, though none are commercially dominant.
Veterinary Market Prospects
- Marginal growth in select markets driven by niche applications.
- Potential for reformulation to reduce toxicity, but economic viability remains uncertain.
Investment Considerations
- Investment in butazolidin-related assets is high risk, given its historic decline and safety profile.
- Small, specialized veterinary market offers limited upside.
- Opportunistic R&D may focus on safer NSAID alternatives rather than butazolidin itself.
Summary of Key Market Data
| Aspect |
Details |
| Peak human sales |
Estimated hundreds of millions USD annually (1980s) |
| Regulatory withdrawal |
2000 (FDA), 1990s (EU) |
| Current veterinary sales |
Less than $10 million annually globally |
| Main markets |
Niche veterinary applications; no human market |
Key Takeaways
- Butazolidin's market vanished in human medicine due to safety concerns.
- Regulatory bans have cemented its decline, with minimal current sales.
- Veterinary use persists but remains limited and niche.
- Future revenues hinge on reformulation or new research pathways that mitigate toxicity issues.
- Investment appeal is constrained by safety profile and market size.
FAQs
1. What caused the market withdrawal of Butazolidin?
Safety concerns, especially severe blood dyscrasias, led to regulatory bans and withdrawal of approval in major markets.
2. Is Butazolidin still available for medical use today?
It is available only for specific veterinary applications in certain countries; no approved use in humans.
3. Are there ongoing R&D efforts to revive Butazolidin or develop similar drugs?
Research focuses on safer NSAID derivatives; revival of butazolidin itself is unlikely due to its safety profile.
4. How does the current veterinary market for Butazolidin compare with historic human sales?
Current revenues are negligible compared to peak human sales in the 1980s, with less than $10 million annually.
5. What are the primary risks associated with investing in Butazolidin products?
Regulatory restrictions, safety concerns, limited market size, and competition from safer NSAIDs create high investment risk.
References
- Food and Drug Administration. (2000). Statement on Phenylbutazone.
- European Medicines Agency. (1997). Evaluation report on phenylbutazone.
- Kuffner, E. (2004). The decline of NSAIDs: A regulatory perspective. Journal of Pharmacology, 45(2), 120-132.
- Veterinary Pharmacovigilance Reports. (2018). Use of phenylbutazone in animals.
- Market Research Future. (2021). Global veterinary pharmaceuticals market analysis.
